Actual Medicinal Product (AMP) Venlafaxine 300mg modified-release tablets (Martindale Pharmaceuticals Ltd)

Stability Information

(Some stability information inherited from generic)

Stability: Lack of data and/or stability concerns exist. MCA use may be acceptable but is likely to be off-label and require mitigation measures. Keep medicines in MCAs for the shortest time necessary. Generally, up to 5 weeks maximum unless otherwise specified, or up to 8 weeks if the MCA is airtight (sealed). Consider the risk of potency loss or dose variability and monitor for changes in efficacy or adverse effects after MCA initiation.
Notes: Moisture sensitive medicine. Store in airtight container. Manufacturer recommends storage in original container. Original packaging may contain desiccant. Anecdotal reports of use in MCAs (low quality evidence)
Provenance: This recommendation is based on the products Venlalic 300mg, prolonged release tablets (Martindale Pharma, an Ethypharm Group Company and Venlafaxine 300mg prolonged release tablets (Ranbaxy (UK) Limited a Sun Pharmaceutical Company).
Generic: Venlafaxine
Formulation: Venlafaxine 300mg modified-release tablets